Reply to correspondence: Basophil reactivity to BNT162b2 in COVID-19 convalescence
- PMID: 35770813
- PMCID: PMC9350273
- DOI: 10.1111/all.15208
Reply to correspondence: Basophil reactivity to BNT162b2 in COVID-19 convalescence
Conflict of interest statement
None of the authors have any conflicts of interest to disclose.
Comment on
-
The value of the basophil activation test in the evaluation of patients reporting allergic reactions to the BNT162b2 mRNA COVID-19 vaccine.Allergy. 2022 Jul;77(7):2067-2079. doi: 10.1111/all.15148. Epub 2021 Oct 31. Allergy. 2022. PMID: 34689351 Free PMC article.
References
-
- Troelnikov A, Perkins G, Yuson C, et al. Basophil reactivity to BNT162b2 is mediated by PEGylated lipid nanoparticles in PEG allergic patients. J Allergy Clin Immunol. 2021;148(1):91‐95. - PubMed
